The Motley Fool
03 May 2026, 12:30 UTC · 21w ago
Verdict
Source says Buy. We score GTBIF +0.80 across four claims.
Score confirms the headline.
Buy
Rating stated in the headline
+0.80strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
The U.S. Department of Justice is reclassifying cannabis from a Schedule I to a Schedule III drug.
More positive than 93% of claims this week
Reclassification to Schedule III removes the IRS Code Section 280E bar, allowing cannabis businesses to deduct ordinary business expenses.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More positive than 87% of claims this week
Trulieve's effective tax rate is expected to drop from 60%-70% to approximately 21% due to the removal of 280E rules.
More positive than 78% of claims this week
The market impact of the rescheduling is primarily limited to medical marijuana operators rather than the broader sector.
More negative than 77% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company is positioned as a top pick for institutional investors with expected margin expansion in the reclassified era.
More positive than 88% of ticker scores this week
The company is expected to see a significant increase in profitability due to the removal of the 280E tax burden following cannabis reclassification.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
−3.1%
Price is moving against the score
$7.75 vs $8.00 close before publication (May 1) · not market-adjusted
GTBIF chart →
